InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Thursday, 07/04/2019 12:10:21 PM

Thursday, July 04, 2019 12:10:21 PM

Post# of 48
News: $GRFS Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

BARCELONA, Spain , July 4, 2019 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify ® , its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (F...

Read the whole news Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GRFS News